Heron Therapeutics Q4 2023 Earnings Report

Heron Therapeutics EPS Results

• Actual EPS: -$0.07
• Consensus EPS: -$0.15
• Beat/Miss: Beat by +$0.08
• One Year Ago EPS: N/A

Heron Therapeutics Revenue Results

• Actual Revenue: $34.23 million
• Expected Revenue: $30.98 million
• Beat/Miss: Beat by +$3.25 million
• YoY Revenue Growth: N/A

Heron Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/12/2024
• Time: N/A

Heron Therapeutics (NASDAQ:HRTX), a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.